Cadent Therapeutics, currently undergoing acquisition by Novartis, is developing novel medicines that tune and modulate brain rhythms to restore cognitive and motor function in patients with serious neurological disease. Currently in early clinical development, Cadent is rapidly advancing its pipeline of therapies to treat spinocerebellar ataxia, essential tremor and schizophrenia. Cadent’s subtype selective NMDA receptor negative allosteric modulation technology for the treatment of depression is licensed to Novartis.